Insulet Corp. (NSDQ:PODD) inked a Canadian distribution deal with GlaxoSmithKline plc (NYSE:GSK) for its OmniPod insulin management system.

The deal gives the British pharma giant — stung by recent problems with its Avandia diabetes drug — exclusive rights to market and sell Bedford, Mass.-based Insulet’s OmniPod system north of the border.